Hubungan Kadar Vascular Endothelial Growth Factor (VEGF) Serum dengan Skor Psoriasis Area And Severity Index (PASI) pada penderita psoriasis vulgaris di RSUP. H. Adam Malik Medan
61
DAFTAR PUSTAKA
1. Sinniah B, Devi SS, Prashant BS. Epidemiology of Psoriasis in Malaysia:
A Hospital Based Study. Med J Malaysia. 2010;65(2):112
2. Traub M, Marshall K. Psoriasis-Pathophysiology, conventional, and
alternative approaches to treatment. Altern Med Rev. 2007;12(4):319-30
3. Gudjonsson J, Elder JT. Psoriasis: epidemiology. Clin Dermatol.
2012;18:377
4. Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis.
Expert Rev. Dermatol. 2006;1(1):63-75
5. Ortonne JP. Recent developments in the understanding of the patogenesis
of psoriasis. Br J Dermatol. 1999;54: 1-7
6. Bos JD, De Rie MA. The patogenesis of psoriasis: immunological facts
and speculations. Immunol Today. 1999; 20: 40-6
7. Suomela S. Studies on the molecular patogenesis of psoriasis. Helsinki
University Biomedical Dissertations. 2004; 52:1-81
8. Flisiak I, Przemysław Z, Magdalena R. Effect of psoriasis activity on
VEGF and its soluble receptors concentrations in serum and plaque scales.
2010. Cytokine.2013;61: 690
9. Neufeld G, Cohen T,Gengrinovitch S, Poltorak Z. Vascular endothelial
growth factor (VEGF) and its receptors. The FASEB Journal. 1999; 14:117
10. Glickman FS. Lepra, psora, psoriasis. J Am Acad Dermatol. 1986; 14(5 Pt
1):863-6
11. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005; 352: 1899–912
12. Darouti ME, Hay RA. Psoriasis: Highlights on patogenesis, adjuvant
therapy and treatment of resistant and problematic cases (part I). J Egypt
Women Dermatol Soc. 2010; 7: 64–70
13. Nograles KE, Brasington RD, Bowcock AM. New insights into the
patogenesis and genetiks of psoriatik arthritis. Nat Clin Pract Rheumatol.
2009;5(2):83-91
14. Lowes MA, Bowcock AM, Krueger JG. Patogenesis and therapy of
psoriasis. Nature. 2007; 445: 866-73
15. Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis
patogenesis. Int J Exp Pathol. 2009; 90(3): 232–48
16. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical
features, and quality of life. Ann Rheum Dis. 2005; 64(Suppl 2): ii18–23.
17. Eedy DJ, Griffiths CE, Chalmers RJ. The assessment and management of
psoriasis. NICE Clinical Guidelines 2012;153:34-5
Universitas Sumatera Utara
62
18. Smith, A.V. Barker, A.D. British Association of Dermatologists’
guidelines for biologic interventions for psoriasis. British Journal of
Dermatology. 2009;161: 987–1019
19. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann
Rheum Dis 2005;64:65-8
20. Nofal A, Vascular endothelial growth factor in psoriasis: an indicator of
disease severity and control. J Eur Acad Dermatol Venereol. 2009
Jul;23(7):803-6.
21. Nielsen HJ, Christensen IJ, Svendsen MN, Hansen U, Werther K, Brünner
N, Petersen LJ, Kristensen JK. Elevated plasma levels of vascular
endothelial growth factor and plasminogen activatorinhibitor-1 decrease
during improvement of psoriasis. Inflamm Res. 2002;51(11):563-7.
22. Puxeddu I, Ribatti D, Crivellato E, Schaffer FL. Mast cells and
eosinophils: A novel link between inflammation and angiogenesis in
allergic diseases. J Allergy Clin Immunol. 2005;116:531-6
23. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/
VEGF receptor system and its role under physiological and pathological
conditions.Clinical Science. 2005; 109: 227–41
24. Dvorak FH. Vascular Permeability Factor/Vascular Endothelial Growth
Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target
for Diagnosis and Therapy. J Clin Oncol.2002; 20:4368-80.
25. Olsson AK, Dimberg A, Kreuger J, Welsh LC. VEGF receptor signalingin control of vascular function. Molecular Cell Biology. 2006; 7: 359-69.
26. Weidemann AK, Crawshaw AA, Young HS. Vascular endothelial growth
factor inhibitors: investigational therapies for the treatment of psoriasis.
Clin Cosmet Investig Dermatol. 2013; 6: 233–44.
27. Schonthaler HB, Huggenberger R, Wculek SK, Detmar W, Wagner EF.
Systemic anti-VEGF treatment strongly induces reduces skin
inflammation in a mouse model of psoriasis. PNAS. 2005; 106(50): 212649
28. Zablotna M, Sobjanek M, Nedoszytko B, Lange M, Kozicka D, Glen J,
Roszkiewicz. Association of psoriasis with VEGF gene polymorphism in
the northern Polish population. J Eur Acad Dermatol Venerol. 2011;
134(1):71-80
29. Cimmino MA. Epidemiology of psoriasis and psoriasis arthritis.
Reumatismo. 2007;59(1):19-24
30. Chang YT, Chen TJ, Liu PC et al. Epidemiological study of psoriasis in
the national health insurance database in Taiwan. Acta Derm Venereol.
2009; 89:262–6
Universitas Sumatera Utara
63
31. Lin TY, et al. Quality of Life in Patients with Psoriasis in Northern
Taiwan. Chang Gung Med J. 2011;34:186-96
32. Lin TF. Modifiable health risk factors and medical expenditures – the case
of Taiwan. Soc Sci Med. 2008; 67: 1727–36.
33. Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad
Dermatol. 1984;10:965-8.
34. Subagio, Thaha MA, Rusmawardiana, Tjekyan RM. Hubungan Profil
Lipid dengan Keparahan Psoriasis di RSUP DR. Mohammad Hoesin
Palembang [disertasi]. Palembang: Universitas Sriwijaya; 2011.
35. Setyorini M, Triestianawati W, Wiryadi BE, Alam Jacoeb TN. Proporsi
Sindrom Metabolik pada Penderita Psoriasis Vulgaris Berdasarkan
Kriteria National Cholesterol Education Program Adult Treatment Panel
III di RS DR. Cipto Mangunkusumo dan Sebuah Klinis Swasta Di Jakarta.
MDVI. 2012; 39(1):2-9
36. Budiastuti A, Sugianto R. Hubungan Umur dan Lama Sakit Terhadap
Derajat Keparahan Penderita Psoriasis. M Med Ind. 2009; 43: 312-6
37. Fatani MI, Abdulghani MM, Al-Afif KA: Psoriasis in the eastern Saudi
Arabia. Saudi Med J. 2002; 23: 213-7
38. Chen HH, Tseng MP, Tsai TF. An epidemiologic study of Taiwanese
psoriatic patients in a single clinic. Dermatolo Sinica . 2003; 21: 216–24
39. Brandrup F, Green A: The prevalence of psoriasis in Denmark. Acta Derm
Venereol. 1981; 61: 344-6
40. Hellgren L. Psoriasis. The Prevalence in Sex, Age and Occupational
Groups in Total Populations in Sweden. Skin and Rheumatic Diseases.
1967; 256
41. Cooperative Psoriasis Study Group Distribution of psoriasis in China: A
nationwide screening in 1984. Chinese Journal of Dermatology. 1986;
19:253–62
42. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis
in people with psoriasis. Arthritis and Rheumatism. 2009; 61(10):1373-8
43. Artana IP, Gautama A, Adiguna MS, Karmila D. Psoriasis Inversa dan
Kandidiasis Kutis Intertriginosa pada Bayi [disertasi]. Denpasar, Bali:
2011.
44. Stern RS, Nijsten T, Feldman SR et al. Psoriasis is common, carries a
substantial burden even when not extensive, and is associated with
widespread treatment dissatisfaction. J Investig Dermatol Symp Proc.
2004; 9:136–9
45. Olsen AO, Grjibovski A, Magnus P, Tambs K, Harris JR. Psoriasis in
Norway as observed in a population based Norwegian twin panel. Br J
Dermatol. 2005; 153;346-51
Universitas Sumatera Utara
64
46. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis
DJ. Prevalence and treatment of psoriasis in the United Kingdom. A
population based Study. Arch Dermatol.2005; 141:1537-41
47. Parisi S, Symmons D, Griffiths C, Ashcroft DM. Global Epidemiology of
Psoriasis: A Systematic Review of Incidence and Prevalence.Journal of
investigative dermatology. 2013; 133: 377-85
48. Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis.
Expert Rev. Dermatol. 2006;1(1):63-75
49. Chang YT, Chen TJ, Liu PC et al. Epidemiological study of psoriasis in
the national health insurance database in Taiwan. Acta Derm Venereol.
2009; 89:262–6
50. Diallo M. Psoriasis Epidemiology. J Clinic Case Reports. 2012; 2: 8
51. Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H.
Serum cytokines and growth factor levels in Japanese patients with
psoriasis. Clin Exp. Dermatol. 2010; 35: 645–9
52. Shimauchi T, Hirakawa S, Suzuki T, Yasuma A, Majima Y, Tatsuno K et
al. Serum interleukin-22 and vascular endothelial growth factor serve as
sensitive biomarkers but not as predictors of therapeutic response to
biologics in patients with psoriasis. Journal of Dermatology. 2013; 40:
805–12
53. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures
for assessing plaque psoriasis severity? A systematic review of the
literature. J Eur Acad Dermatol Venereol. 2010 24 (Suppl 2):10-16.
54. Al-Shobaili H. Serum vascular endothelial growth factor, transforming
growth factor-b1 and nitric oxide levels in patients with psoriasis vulgaris:
Their correlation to disease severity. J Clin Exp Dermatol Res. 2014, 5:2
55. Martin G, Guerard S, Fortin MM et al. Pathological crosstalk in vitro
between T lymphocytes and lesional keratinocytes in psoriasis: necessity
of direct cell-to-cell contact. Laboratory investigation. 2012; 92: 1058-70
Universitas Sumatera Utara
DAFTAR PUSTAKA
1. Sinniah B, Devi SS, Prashant BS. Epidemiology of Psoriasis in Malaysia:
A Hospital Based Study. Med J Malaysia. 2010;65(2):112
2. Traub M, Marshall K. Psoriasis-Pathophysiology, conventional, and
alternative approaches to treatment. Altern Med Rev. 2007;12(4):319-30
3. Gudjonsson J, Elder JT. Psoriasis: epidemiology. Clin Dermatol.
2012;18:377
4. Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis.
Expert Rev. Dermatol. 2006;1(1):63-75
5. Ortonne JP. Recent developments in the understanding of the patogenesis
of psoriasis. Br J Dermatol. 1999;54: 1-7
6. Bos JD, De Rie MA. The patogenesis of psoriasis: immunological facts
and speculations. Immunol Today. 1999; 20: 40-6
7. Suomela S. Studies on the molecular patogenesis of psoriasis. Helsinki
University Biomedical Dissertations. 2004; 52:1-81
8. Flisiak I, Przemysław Z, Magdalena R. Effect of psoriasis activity on
VEGF and its soluble receptors concentrations in serum and plaque scales.
2010. Cytokine.2013;61: 690
9. Neufeld G, Cohen T,Gengrinovitch S, Poltorak Z. Vascular endothelial
growth factor (VEGF) and its receptors. The FASEB Journal. 1999; 14:117
10. Glickman FS. Lepra, psora, psoriasis. J Am Acad Dermatol. 1986; 14(5 Pt
1):863-6
11. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005; 352: 1899–912
12. Darouti ME, Hay RA. Psoriasis: Highlights on patogenesis, adjuvant
therapy and treatment of resistant and problematic cases (part I). J Egypt
Women Dermatol Soc. 2010; 7: 64–70
13. Nograles KE, Brasington RD, Bowcock AM. New insights into the
patogenesis and genetiks of psoriatik arthritis. Nat Clin Pract Rheumatol.
2009;5(2):83-91
14. Lowes MA, Bowcock AM, Krueger JG. Patogenesis and therapy of
psoriasis. Nature. 2007; 445: 866-73
15. Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis
patogenesis. Int J Exp Pathol. 2009; 90(3): 232–48
16. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical
features, and quality of life. Ann Rheum Dis. 2005; 64(Suppl 2): ii18–23.
17. Eedy DJ, Griffiths CE, Chalmers RJ. The assessment and management of
psoriasis. NICE Clinical Guidelines 2012;153:34-5
Universitas Sumatera Utara
62
18. Smith, A.V. Barker, A.D. British Association of Dermatologists’
guidelines for biologic interventions for psoriasis. British Journal of
Dermatology. 2009;161: 987–1019
19. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann
Rheum Dis 2005;64:65-8
20. Nofal A, Vascular endothelial growth factor in psoriasis: an indicator of
disease severity and control. J Eur Acad Dermatol Venereol. 2009
Jul;23(7):803-6.
21. Nielsen HJ, Christensen IJ, Svendsen MN, Hansen U, Werther K, Brünner
N, Petersen LJ, Kristensen JK. Elevated plasma levels of vascular
endothelial growth factor and plasminogen activatorinhibitor-1 decrease
during improvement of psoriasis. Inflamm Res. 2002;51(11):563-7.
22. Puxeddu I, Ribatti D, Crivellato E, Schaffer FL. Mast cells and
eosinophils: A novel link between inflammation and angiogenesis in
allergic diseases. J Allergy Clin Immunol. 2005;116:531-6
23. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/
VEGF receptor system and its role under physiological and pathological
conditions.Clinical Science. 2005; 109: 227–41
24. Dvorak FH. Vascular Permeability Factor/Vascular Endothelial Growth
Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target
for Diagnosis and Therapy. J Clin Oncol.2002; 20:4368-80.
25. Olsson AK, Dimberg A, Kreuger J, Welsh LC. VEGF receptor signalingin control of vascular function. Molecular Cell Biology. 2006; 7: 359-69.
26. Weidemann AK, Crawshaw AA, Young HS. Vascular endothelial growth
factor inhibitors: investigational therapies for the treatment of psoriasis.
Clin Cosmet Investig Dermatol. 2013; 6: 233–44.
27. Schonthaler HB, Huggenberger R, Wculek SK, Detmar W, Wagner EF.
Systemic anti-VEGF treatment strongly induces reduces skin
inflammation in a mouse model of psoriasis. PNAS. 2005; 106(50): 212649
28. Zablotna M, Sobjanek M, Nedoszytko B, Lange M, Kozicka D, Glen J,
Roszkiewicz. Association of psoriasis with VEGF gene polymorphism in
the northern Polish population. J Eur Acad Dermatol Venerol. 2011;
134(1):71-80
29. Cimmino MA. Epidemiology of psoriasis and psoriasis arthritis.
Reumatismo. 2007;59(1):19-24
30. Chang YT, Chen TJ, Liu PC et al. Epidemiological study of psoriasis in
the national health insurance database in Taiwan. Acta Derm Venereol.
2009; 89:262–6
Universitas Sumatera Utara
63
31. Lin TY, et al. Quality of Life in Patients with Psoriasis in Northern
Taiwan. Chang Gung Med J. 2011;34:186-96
32. Lin TF. Modifiable health risk factors and medical expenditures – the case
of Taiwan. Soc Sci Med. 2008; 67: 1727–36.
33. Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad
Dermatol. 1984;10:965-8.
34. Subagio, Thaha MA, Rusmawardiana, Tjekyan RM. Hubungan Profil
Lipid dengan Keparahan Psoriasis di RSUP DR. Mohammad Hoesin
Palembang [disertasi]. Palembang: Universitas Sriwijaya; 2011.
35. Setyorini M, Triestianawati W, Wiryadi BE, Alam Jacoeb TN. Proporsi
Sindrom Metabolik pada Penderita Psoriasis Vulgaris Berdasarkan
Kriteria National Cholesterol Education Program Adult Treatment Panel
III di RS DR. Cipto Mangunkusumo dan Sebuah Klinis Swasta Di Jakarta.
MDVI. 2012; 39(1):2-9
36. Budiastuti A, Sugianto R. Hubungan Umur dan Lama Sakit Terhadap
Derajat Keparahan Penderita Psoriasis. M Med Ind. 2009; 43: 312-6
37. Fatani MI, Abdulghani MM, Al-Afif KA: Psoriasis in the eastern Saudi
Arabia. Saudi Med J. 2002; 23: 213-7
38. Chen HH, Tseng MP, Tsai TF. An epidemiologic study of Taiwanese
psoriatic patients in a single clinic. Dermatolo Sinica . 2003; 21: 216–24
39. Brandrup F, Green A: The prevalence of psoriasis in Denmark. Acta Derm
Venereol. 1981; 61: 344-6
40. Hellgren L. Psoriasis. The Prevalence in Sex, Age and Occupational
Groups in Total Populations in Sweden. Skin and Rheumatic Diseases.
1967; 256
41. Cooperative Psoriasis Study Group Distribution of psoriasis in China: A
nationwide screening in 1984. Chinese Journal of Dermatology. 1986;
19:253–62
42. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis
in people with psoriasis. Arthritis and Rheumatism. 2009; 61(10):1373-8
43. Artana IP, Gautama A, Adiguna MS, Karmila D. Psoriasis Inversa dan
Kandidiasis Kutis Intertriginosa pada Bayi [disertasi]. Denpasar, Bali:
2011.
44. Stern RS, Nijsten T, Feldman SR et al. Psoriasis is common, carries a
substantial burden even when not extensive, and is associated with
widespread treatment dissatisfaction. J Investig Dermatol Symp Proc.
2004; 9:136–9
45. Olsen AO, Grjibovski A, Magnus P, Tambs K, Harris JR. Psoriasis in
Norway as observed in a population based Norwegian twin panel. Br J
Dermatol. 2005; 153;346-51
Universitas Sumatera Utara
64
46. Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis
DJ. Prevalence and treatment of psoriasis in the United Kingdom. A
population based Study. Arch Dermatol.2005; 141:1537-41
47. Parisi S, Symmons D, Griffiths C, Ashcroft DM. Global Epidemiology of
Psoriasis: A Systematic Review of Incidence and Prevalence.Journal of
investigative dermatology. 2013; 133: 377-85
48. Neimann AL, Porter SB, Gelfand JM. The epidemiology of psoriasis.
Expert Rev. Dermatol. 2006;1(1):63-75
49. Chang YT, Chen TJ, Liu PC et al. Epidemiological study of psoriasis in
the national health insurance database in Taiwan. Acta Derm Venereol.
2009; 89:262–6
50. Diallo M. Psoriasis Epidemiology. J Clinic Case Reports. 2012; 2: 8
51. Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H.
Serum cytokines and growth factor levels in Japanese patients with
psoriasis. Clin Exp. Dermatol. 2010; 35: 645–9
52. Shimauchi T, Hirakawa S, Suzuki T, Yasuma A, Majima Y, Tatsuno K et
al. Serum interleukin-22 and vascular endothelial growth factor serve as
sensitive biomarkers but not as predictors of therapeutic response to
biologics in patients with psoriasis. Journal of Dermatology. 2013; 40:
805–12
53. Puzenat E, Bronsard V, Prey S, et al. What are the best outcome measures
for assessing plaque psoriasis severity? A systematic review of the
literature. J Eur Acad Dermatol Venereol. 2010 24 (Suppl 2):10-16.
54. Al-Shobaili H. Serum vascular endothelial growth factor, transforming
growth factor-b1 and nitric oxide levels in patients with psoriasis vulgaris:
Their correlation to disease severity. J Clin Exp Dermatol Res. 2014, 5:2
55. Martin G, Guerard S, Fortin MM et al. Pathological crosstalk in vitro
between T lymphocytes and lesional keratinocytes in psoriasis: necessity
of direct cell-to-cell contact. Laboratory investigation. 2012; 92: 1058-70
Universitas Sumatera Utara